E156 Micro-Paper · Africa Clinical Trials

Bayesian Trial Penetration

Bayesian methods are ideally suited for Africa's small-sample reality — incorpor...

Africa Trials
13
US Trials
476
Gap Ratio
37x
Nations
54
Africa hosts 23,873 trials across 54 nations with extreme geographic concentration.
No data
Bayesian Trial Penetration by Country Egypt: 11752 Algeria: N/A Morocco: 162 Tunisia: 540 Senegal: N/A Ghana: 261 Nigeria: 379 Cameroon: N/A DRC: N/A Ethiopia: 302 Kenya: 788 Uganda: 809 Tanzania: 460 Rwanda: N/A South Africa: 3654 Egy 11752 Sou 3654 Uga 809 Ken 788 Tun 540 162 11752
Regional Comparison Africa US Europe 0 200 400 600
Contribution Breakdown 11752 Egypt 3654 South Afri 809 Uganda 788 Kenya 540 Tunisia 2814 Others
Research Profile Volume Growth Phase3 Complete Diversity
Enrollment Distribution Africa Reference 1000 2000 3000 4000 5000
No data
Growth 2010-2026 Before After Africa 0 0 US 0 0 Europe 0 0
Why It Matters

Bayesian methods are ideally suited for Africa's small-sample reality — incorporating prior knowledge to strengthen inference — yet Bayesian trial designs remain extremely rare on the continent.

In the methodological architecture of African clinical research, does the pattern of bayesian trial penetration reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the Bayesian posterior trial rate as the primary estimand using registry metadata for each nation. Africa registered 13 relevant trials compared to 476 in the United States, revealing an 37-fold absolute gap in research volume. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These results indicate that methodological capacity gaps limit the quality and impact of African clinical research output. Interpretation is limited by the use of a single registry and the absence of non-English trial databases.
Question

In the methodological architecture of African clinical research, does the pattern of bayesian trial penetration reveal structural inequity in African research investment?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the Bayesian posterior trial rate as the primary estimand using registry metadata for each nation.

Robustness

Africa registered 13 relevant trials compared to 476 in the United States, revealing an 37-fold absolute gap in research volume.

Interpretation

Temporal analysis showed 17.

Boundary

1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.

Extra

These results indicate that methodological capacity gaps limit the quality and impact of African clinical research output.

Extra

Interpretation is limited by the use of a single registry and the absence of non-English trial databases.